我院4种靶向抗肿瘤药物不良反应的调查与分析

摘要

Objective:To study and analyze our hospital adverse reactions in four targeted anticancer drugs.Methods: A hospital in December 2011 to December 2012 were treated 30 cases of premature ovarian failure patients for the study, the hospital in January 2013 to April 2014 were treated 100 cases of diagnosed cancer patients included in this study, this group of patients receiving chemotherapy, this group of patients were treated with erlotinib, gefitinib (Iressa), rituximab (MabThera), cetuximab (Erbitux) for treatment analyzed the incidence of adverse reactions.Results: 100 patients, erlotinib, gefitinib (Iressa), rituximab(MabThera), cetuximab(Erbitux) prescriptions were 187,119,245 312, adverse events rates were 12.5%, 13.3%, 7.1%, 12.1%. Roughly, compared with conventional anticancer drugs in terms of the foreign reports, the incidence of adverse drug reactions is relatively low, low degree of adverse reactions, mostly for Class I and Class II, not a threat to the safety of patients.Conclusion: Adverse reactions erlotinib, gefitinib (Iressa), rituximab (MabThera), cetuximab (Erbitux)caused relatively few, including rituximab lower incidence of adverse reactions, however, the sample size in this study is less choice, remains to be further studied.%目的：调查并分析我院4种靶向抗肿瘤药物的不良反应。方法：将我院2013年1月～2014年4月收治的100例确诊为恶性肿瘤的患者纳入本研究，本组患者均接受化疗，采用厄洛替尼、吉非替尼（易瑞沙）、利妥昔单抗（美罗华）、西妥昔单抗（爱必妥）进行治疗，分析其不良反应情况。结果：100例患者中，厄洛替尼、吉非替尼（易瑞沙）、利妥昔单抗（美罗华）、西妥昔单抗（爱必妥）处方量分别为187、119、245、312，不良反应发生率分别为12.5%、13.3%、7.1%，12.1%，与国外报道大致相当。与传统抗肿瘤药物相比，这些药物的不良反应发生率相对较低，不良反应程度也较轻，多为I级与II级，不会危及患者的生命安全。结论：厄洛替尼、吉非替尼（易瑞沙）、利妥昔单抗（美罗华）、西妥昔单抗（爱必妥）引发的不良反应相对较少，利妥昔单抗不良反应发生率较低，但是，本研究选择的样本量较少，还有待进一步的调查研究。